News 8’s Dennis House sat down with the founder to talk about how his company has helped businesses across the nation and right here in Connecticut.,RELATED: Founder of Barstool Sports wants everyone to know: New Haven is the pizza capital of the U.S.,All across the state, restaurants like the Red Rock are going through tough times due to the pandemic and Dave Portnoy, the founder of lifestyle brand Barstool Sports, wants to help.,RELATED: Elmer’s Place in New Britain latest CT restaurant to get help from Barstool amid pandemic crisis

Portnoy explained what he is looking for in a restaurant looking to get help from the Barstool Fund: “Red Rock is a perfect example of the two things we look for: a long track record of success…The second thing we look for is that the business owner still paid their employees.”,At the Red Rock, they are grateful for Barstool and Portnoy: “We can’t thank him enough. read more

A paper published in the journal Nature Communications, reveals a potential revolutionary drug combination that -- in animal studies and in world-first 3D models of the tumour -- is "spectacularly effective in eradicating the cancer cells," according to lead researcher and paediatric oncologist Associate Professor c from the Children's Cancer Institute and Sydney Children's Hospital.,These models have been used to show that DIPG can bypass the activity of DFMO by pumping polyamines into cancer, essentially allowing the tumour to continue growing despite treatment with DFMO.,They have now made the breakthrough discovery that treatment with a new developmental drug, AMXT 1501, potently blocks the transport of polyamines into the DIPG cancer cell.,Treatment with AMXT 1501 was found to re-sensitize the DIPG cells to DFMO leading to what Associate Professor Ziegler said, "was a spectacular response in animal models, with a significantly increased survival and minimal toxicity (side effects).",Associate Professor Ziegler said that clinical trials of the drug combination in DIPG are planned to begin this year in children in a global study led by the Children's Cancer Institute and the Kid's Cancer Centre at Sydney Children's Hospital.

A paper published today 12 Feb 2021 in the prestigious journal, Nature Communications, reveals a potential revolutionary drug combination that - in animal studies and in world-first 3D models of the tumor - is "spectacularly effective in eradicating the cancer cells," according to lead researcher and pediatric oncologist Associate Professor David Ziegler, from the Children's Cancer Institute and Sydney Children's Hospital.,These models have been used to show that DIPG can bypass the activity of DFMO by pumping polyamines into cancer, essentially allowing the tumor to continue growing despite treatment with DFMO.,They have now made the breakthrough discovery that treatment with a new developmental drug, AMXT 1501, potently blocks the transport of polyamines into the DIPG cancer cell.,Treatment with AMXT 1501 was found to re-sensitize the DIPG cells to DFMO leading to what Associate Professor Ziegler said, "was a spectacular response in animal models, with a significantly increased survival and minimal toxicity (side effects)".,Associate Professor Ziegler said that clinical trials of the drug combination in DIPG are planned to begin this year in children in a global study led by the Children's Cancer Institute and the Kid's Cancer Centre at Sydney Children's Hospital.

A paper published in the journal Nature Communications, reveals a potential revolutionary drug combination that -- in animal studies and in world-first 3D models of the tumour -- is "spectacularly effective in eradicating the cancer cells," according to lead researcher and paediatric oncologist Associate Professor c from the Children's Cancer Institute and Sydney Children's Hospital.,These models have been used to show that DIPG can bypass the activity of DFMO by pumping polyamines into cancer, essentially allowing the tumour to continue growing despite treatment with DFMO.,They have now made the breakthrough discovery that treatment with a new developmental drug, AMXT 1501, potently blocks the transport of polyamines into the DIPG cancer cell.,Treatment with AMXT 1501 was found to re-sensitize the DIPG cells to DFMO leading to what Associate Professor Ziegler said, "was a spectacular response in animal models, with a significantly increased survival and minimal toxicity (side effects).",Associate Professor Ziegler said that clinical trials of the drug combination in DIPG are planned to begin this year in children in a global study led by the Children's Cancer Institute and the Kid's Cancer Centre at Sydney Children's Hospital.